ASPI

ASP Isotopes Inc. (ASPI) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. ASP Isotopes Inc. is an advanced materials company developing isotope enrichment technologies (ASP and QE) for nuclear medicine, semiconductors, and nuclear energy. The quarter was defined by significant corporate restructuring, including the acquisition of Renergen (natural gas, helium, and LNG producer) and the deconsolidation of Skyline (construction services), which is now reported as discontinued operations. The company operates through three segments: Specialist Isotopes and Related Services, Nuclear Fuels, and Helium and LNG.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 279% to $4.18 million, driven by the inclusion of Renergen (LNG sales) and expanded radiopharmacy operations (PET/SPECT). Collaboration revenue of $0.2 million was recognized from TerraPower.
• Operating Expenses: Total operating expenses surged to $26.55 million from $8.28 million. This increase is primarily due to the consolidation of Renergen, increased headcount, and higher professional fees related to acquisitions.
• Debt Structure: Total debt increased significantly to $58.33 million, largely due to the assumption of Renergen's debt obligations (including loans from DFC, IDC, and Standard Bank of South Africa). Convertible notes payable increased to $199.89 million following the conversion of 2024 notes into 2025 notes.
• Discontinued Operations: The deconsolidation of Skyline resulted in a gain of $19.3 million, which significantly reduced the reported Net Loss from continuing operations to a total Net Loss of $7.12 million.
• Foreign Exchange: A foreign exchange transaction loss of $3.73 million impacted other income/expense, compared to $0.06 million in the prior year.

Guidance, Outlook, and Risks

• Commercialization Timeline: The company targets initial commercial shipments of enriched C-14 and Yb-176 in Q3 2026, and Si-28 around mid-year 2026. Helium liquefaction at the Virginia Gas Project is targeted for H2 2026.
• Strategic Separation: Management intends to list Quantum Leap Energy (QLE) as a standalone public company, potentially via an IPO, to separate the nuclear fuels business from specialist isotopes.
• Liquidity: Management believes cash and short-term investments ($290.5 million combined) are sufficient to fund operations for more than 12 months. However, the company expects to continue incurring net losses and may require additional capital.
• Key Risks:
  • Debt Covenants: Renergen's subsidiary Tetra4 is currently not in compliance with certain financial covenants under the IDC Loan and is seeking a waiver/deferral. The SBSA Loan is also subject to amendment discussions regarding repayment dates.
  • Regulatory Approval: Success depends on obtaining regulatory approvals for uranium enrichment and isotope production.
  • Legal Proceedings: A securities class action has reached an agreement-in-principle for settlement. Derivative actions and a loan dispute with Molopo Energy remain pending.
  • Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, which were not remediated as of March 31, 2026.

Investor Verification Checklist

• Debt Covenant Status: Verify the outcome of negotiations with the Industrial Development Corporation (IDC) and Standard Bank of South Africa regarding covenant waivers and loan amendments.
• Settlement Terms: Monitor the final court approval and terms of the securities class action settlement.
• QLE IPO Progress: Track the status of the proposed separation and IPO of Quantum Leap Energy (QLE).
• Isotope Production Milestones: Confirm the timeline for initial commercial shipments of C-14, Si-28, and Yb-176 against the stated Q3 2026 targets.
• Remediation Plan: Review updates on the remediation of material weaknesses in internal controls over financial reporting.